Navigation Links
Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
Date:9/18/2007

INDIANAPOLIS, Sept. 18 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that Robert J. Heine, M.D., Ph.D., F.R.C.P., will join Lilly in January, 2008, as Executive Medical Director for the Diabetes and Endocrine division responsible for development of Lilly's expanding diabetes and obesity R&D portfolio. Dr. Heine replaces Dr. Meng Hee Tan, Distinguished Medical Fellow, Diabetes and Endocrine, who will retire at the end of September after 8 years of outstanding service to the company.

"Lilly has a growing and exciting diabetes and obesity R&D portfolio that demands exceptional clinical leadership to guide and successfully develop," said Vince Mihalik, Vice President and Global Brand Development Platform Leader, Diabetes, Obesity and Endocrine. "Robert is widely recognized and respected in the diabetes community for his scientific and clinical excellence and his considerable leadership abilities. He'll be a fantastic addition to the Lilly team."

Heine is currently professor of diabetology in the Department of Endocrinology and director of the Diabetes Centre at the VU (Vrije Universiteit) University Medical Center in Amsterdam, Netherlands. In addition to involvement in several research projects, Heine holds positions within the European Association for the Study of Diabetes (EASD), the European Foundation for the Study of Diabetes (EFSD) and the American Diabetes Association (ADA), including chair of the EASD subcommittee for Clinical Research Training, president of the organizing committee for the 2007 EASD annual meeting, and a member of the ADA Expert Committee on guidelines for the treatment of hyperglycemia in type 2 diabetes. He is a prolific author, with more than 350 published papers, and currently serves as associate editor of Diabetic Medicine and an editorial board member for several other publications. Heine's primary research interests include the epidemiology and pathophysiology of type 2 diabetes.

"We couldn't be more pleased that Dr. Heine has decided to bring his considerable talents to Lilly," said David Moller, M.D., Vice President, Endocrine and Cardiovascular Research and Clinical Investigation, Lilly Research Laboratories. "Robert's outstanding clinical experience and depth of scientific expertise will be a major contributor to the sustained leadership of Lilly in diabetes and related metabolic disorders as we continue to bring novel medicines to patients in need around the world."

"It's a privilege to join a team with such an impressive history of innovation and one that is also shaping the future of diabetes care," said Heine. "I'm excited for the opportunity to work in a new and dynamic atmosphere at Lilly with a group of truly talented scientists."

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Crohns Patient Robert Hill’s greatest achievemen
2. Relapse in Risk Management System Claims the Life of Robertson
3. Robert Wood Johnson Foundation Pledges $500M To Fund Anti-Obesity Programs
4. Distinguished Scientist Award Conferred on Manchester Dentist
5. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
6. Is Diabetes the Leading Cause of Kidney Failure in India
7. Diabetes and Depression often go hand-in-hand
8. Vitamin E, the latest warrior against diabetes
9. Thirty minutes of work up per day reduces the risk of Diabetes
10. New Drug for Diabetes
11. Diabetes, obesity rates shooting up
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s ... ostomy patients, standing as living proof that attitude and determination can combine into ... issues that spike around the holidays. This campaign will offer patients a new-found ...
(Date:12/2/2016)... Honolulu, Hawaii (PRWEB) , ... December 02, 2016 ... ... 3, 2016 at the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, ... (CME) in the field of pain management. , The demand for supplemental ...
(Date:12/2/2016)... Aliso Viejo, California (PRWEB) , ... December 02, 2016 , ... ... that will allow FCPX editors to create versatile lower third titles with just a ... , Pro3rd Accents Volume 2 includes 30 lower third animations. Choose from various ...
(Date:12/2/2016)... ... ... ‘Tis the season for giving! Today, 20 creative teams across the nation found ... Drug Enforcement Administration as part of the National Red Ribbon Week Photo Contest. The ... their campuses with this year’s Red Ribbon Week theme: “YOLO. Be Drug Free,” earn ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center ... has announced the opening of a new eating disorder treatment center location in ... treatment for adults and adolescents, both males and females ages 10 and older ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 On ... down 1.36%; the Dow Jones Industrial Average edged 0.36% higher, ... 2,191.08, down 0.35%. Losses were broad based as six out ... has initiated research reports on the following Services equities: Myriad ... QGEN ), INC Research Holdings Inc. (NASDAQ: ...
(Date:12/2/2016)... , Dec. 1, 2016 Around the ... country, region and each habitable land present over earth. ... every individual once in a life time this is ... care available until now. Given the steady increase in ... together with the spiraling healthcare costs of treatment, there ...
(Date:12/2/2016)... NEW YORK , December 2, 2016 ... some of its past losses following Trump,s victory early ... growth potential, and fund managers are now predicting an ... look at four equities to see how they have ... CLDX ), Amicus Therapeutics Inc. (NASDAQ: ...
Breaking Medicine Technology: